Following these results, a clinical trial (NCT02236481) has recently been published showing the efficacy of IL-1 inhibition, in terms of RA disease activity and glycated hemoglobin percentage (HbA1c%), as a targeted treatment in patients with RA and type 2 diabetes (T2D). The gene discussed is IL1B; the disease is rheumatoid arthritis.